CN114568526A

CN114568526A - Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof

Info

Publication number: CN114568526A
Application number: CN202011376563.2A
Authority: CN
Inventors: 赵红霞; 刘彪; 李威; 孔小宇; 王雯丹; 司徒文佑
Original assignee: Inner Mongolia Yili Industrial Group Co Ltd
Current assignee: Inner Mongolia Yili Industrial Group Co Ltd
Priority date: 2020-11-30
Filing date: 2020-11-30
Publication date: 2022-06-03

Abstract

The invention provides a maternal emulsified infant formula powder for improving intestinal microenvironment health and application thereof. Specifically, the invention provides an application of breast milk oligosaccharide in preparing infant formula powder for improving intestinal microenvironment health, and also provides infant formula powder with the effect of improving intestinal microenvironment health, wherein the breast milk oligosaccharide is fucosyl oligosaccharide, sialyl oligosaccharide or lacto-N-tetrasaccharide; the improving the intestinal microenvironment health comprises: regulate production of butyric acid in the gut system, increase overall production of short chain fatty acids, be utilized by the gut flora as prebiotics in the gut system and produce gas, reduce production of isobutyric acid and/or isovaleric acid, and/or lower pH to maintain intestinal microenvironment health. According to the technology provided by the invention, the breast milk oligosaccharide is added into the infant formula powder, so that the intestinal microenvironment health can be improved, and the generation of butyric acid can be regulated and controlled.

Description

Mother emulsified infant formula powder for improving intestinal microenvironment health and application thereof

Technical Field

The invention relates to a new application of breast milk oligosaccharide, in particular to an application of breast milk oligosaccharide in preparing infant formula powder with the efficacy of improving intestinal microenvironment health (especially reducing intestinal branched fatty acid), the prepared infant formula powder and a related preparation method.

Background

Breast Milk Oligosaccharides (HMOs) belong to the third most abundant substances in breast Milk, except lactose and fat. The total content varies at various stages of lactation, and is about 12-14g/L in mature milk and about 20-24g/L in colostrum. Each breast milk oligosaccharide has a lactose at the reducing end, mostly polylactosamine as the structural backbone, and fucose, sialic acid, or both, at the chain end. Breast milk oligosaccharides are mainly composed of three major groups: fucosyl oligosaccharide, which is a representative substance of 2 '-fucosyl oligosaccharide and 3' -fucosyl oligosaccharide; sialic acid-based oligosaccharides, including 3 '-sialyllactose and 6' -sialyllactose as representative substances; oligosaccharides formed by a core sugar chain structure containing no fucosyl or sialyl group are typified by lacto-N-tetraose and lacto-N-neotetraose. HMOs are present in individual differences in content and are associated with the lewis secretory component of the nursing mother. Since the raw material of infant formula is usually cow's milk, which usually contains no or very little such oligosaccharides, HMOs constitute a gap that infant formula is expected to approach the breast milk.

The intestinal flora is an important constituent substance of a human intestinal microecosystem and plays an important role in human health. Anaerobic bacilli, bifidobacteria, eubacteria, streptococcus, lactobacillus and the like in the intestinal flora can release metabolites such as Short Chain Fatty Acids (SCFA) mainly comprising acetic acid, propionic acid, butyric acid and the like by fermenting carbohydrates, proteins, lipids and the like. SCFA can regulate various physiological functions of the body and play an important role in regulating the health of the intestinal microenvironment. For example, SCFA provide energy and regulate electrolytes, acetate is a significant source of host energy, propionate is involved in the reversal of pyruvate to glucose, and butyrate is taken up by epithelial cells and is the primary energy source for epithelial cells. SCFA also have anti-inflammatory, intestinal barrier function enhancing and antibacterial effects. The SCFA released by the intestinal flora fermentation can reduce the pH value of the intestinal tract, thereby increasing the growth of beneficial bacteria in the intestinal tract and reducing the proliferation of harmful bacteria. Other physiological functions of SCFA include, among others, reducing the risk of early type I diabetes, reducing anxiety, promoting bone growth, and the like. Butyric acid production is significantly associated with a lower incidence of neonatal skin surface allergies, food allergies and respiratory allergies.

At present, a solution which can generate butyric acid and regulate the micro-ecological health of infants is needed in infant formula powder. The inventor develops a carbohydrate formula close to the carbohydrate composition of breast milk according to the content and the composition of breast milk oligosaccharide, and provides a technical basis for the powder-maternal emulsification of the infant formula in the future. The method is combined with the existing research direction of the mother emulsion, the alpha + beta protein combination of the protein mother emulsion is continuously kept, and a new infant formula powder is developed, so that the digestion and absorption of the infant to the protein are improved, the resistance of the infant is enhanced, and the infant is given double care from the viewpoint of the mother emulsion oligosaccharide.

Disclosure of Invention

The invention aims to provide a new application of breast milk oligosaccharide, in particular to an application of breast milk oligosaccharide in preparing a breast milk emulsion infant formula powder with the effect of improving the intestinal microenvironment.

The invention also aims to provide the maternal emulsion infant formula powder.

The invention also aims to provide application of the maternal emulsified infant formula powder.

The invention finds that some breast milk oligosaccharides have the effect of remarkably improving the intestinal microenvironment health, and particularly shows that the production of butyric acid in an adjustable intestinal system can be regulated, the total production of short-chain fatty acid is increased, the short-chain fatty acid is used as a prebiotic in the intestinal system and is utilized by intestinal flora to produce gas, the production of isobutyric acid and isovaleric acid is reduced, and/or the pH is reduced to maintain the intestinal microenvironment health, so that the new application of the breast milk oligosaccharides is provided.

Specifically, the invention provides an application of breast milk oligosaccharide in preparing food for improving intestinal microenvironment health, wherein the breast milk oligosaccharide is fucosyl oligosaccharide, sialyl oligosaccharide or lacto-N-tetraose.

The invention also provides the infant formula powder with the effect of improving the intestinal microenvironment health, which contains breast milk oligosaccharide, wherein the breast milk oligosaccharide is fucosyl oligosaccharide, sialyl oligosaccharide or lactose-N-tetrasaccharide. Wherein the improving intestinal microenvironment health comprises: the improving the intestinal microenvironment health comprises: regulate production of butyric acid in the gut system, increase overall production of short chain fatty acids, be utilized by the gut flora as prebiotics in the gut system and produce gas, reduce production of isobutyric acid and/or isovaleric acid, and/or lower pH to maintain intestinal microenvironment health.

It is known that human milk oligosaccharides include fucosyllactose, sialyllactose, and the basic sugar chain structure of human milk oligosaccharides without fucosyl or sialyl groups (typical representatives include lacto-N-tetraose and its isomer lacto-N-neotetraose).

Wherein 2 ' -fucosyllactose (2 ' -fucosyllactose, 2 ' -FL or 2FL) is a trisaccharide structure formed by fucose and lactose, and is a representative substance of fucosyl oligosaccharide. This material is commercially available, usually prepared by microbial fermentation, and has the same structure as oligosaccharides found in human milk.

3-fucosyllactose (3-fucosyllactose, 3 '-FL or 3FL) is a trisaccharide structure formed by fucose and lactose, and is an isomer of 2' -fucosyllactose. Is a representative of fucosyl oligosaccharides. The substance is prepared by microbial fermentation, and has the same structure as oligosaccharide found in human milk.

lacto-N-tetraose (LNT), which is a hexasaccharide structure formed by lactose and tetraose, is a representative substance of oligosaccharides having a core sugar chain as a basic structure and containing no fucosyl or sialyl group. The substance is prepared by microbial fermentation, and has the same structure as oligosaccharide found in human milk.

3 ' -sialyllactose (3 ' -sialyllactose, 3 ' -SL or 3SL) is a trisaccharide structure formed by sialic acid and lactose, and is a representative substance of sialyl oligosaccharides. The substance is prepared by microbial fermentation, and has the same structure as oligosaccharide found in human milk.

6 ' -sialyllactose (6 ' -sialyllactose, 6 ' -SL or 6SL) is a trisaccharide structure formed by sialic acid and lactose, and is a representative substance of sialic acid-based oligosaccharides. The substance is prepared by microbial fermentation, and has the same structure as oligosaccharide found in human milk.

According to the specific embodiment of the invention, the infant formula powder with the effect of improving the intestinal microenvironment health comprises 14.2-1515.3mg/100g of breast milk oligosaccharide or 0.02-2.0g/L of breast milk oligosaccharide based on milk.

According to the specific embodiment of the invention, the infant formula powder with the effect of improving the intestinal microenvironment health is infant formula powder, wherein the milk oligosaccharide contains 14.2-1515.3mg/100g, and, the infant formula powder has the total protein content of 10-19 g/100g, the proportion of whey protein to the total protein is 38-70%, the content of alpha-lactalbumin is 1.25-2.5 g/100g, the content of beta-casein is 2.2-4.0 g/100g, the content of fat is 17-29 g/100g, the content of linoleic acid is 2500-4500 mg/100g, the content of alpha-linolenic acid is 330-450 mg/100g, the content of dietary fiber is 0.95-6.3 g/100g, the dietary fiber comprises galacto-oligosaccharide, fructo-oligosaccharide and/or breast milk oligosaccharide, and the content of carbohydrate is 50-57 g/100 g.

The components of the breast milk oligosaccharide-containing breast milk infant formula powder, particularly the components and the proportion of milk protein, fat and oligosaccharide, are closer to those of breast milk, the feeding effect is also closer to that of the breast milk, and the immunity of infants can be improved.

The inventor of the scheme collects primary colostrums and mature colostrums in key areas in China, collects bovine colostrums and mature milk samples, conducts a large amount of research and analysis, emphasizes on the adjustment of microstructure of formula powder, conducts emulsification design on aspects such as protein and fat, and selects specific raw materials to prepare the infant formula powder in a compounding manner, so that the formula powder is closer to breast milk in the aspect of subdivision composition and feeding effect.

The inventor of the scheme analyzes and researches nutrition required by growth and development of infants of 0 to 3 years old, investigates corresponding feeding conditions of various infant milk powders in the market, emphasizes on the adjustment of microstructure of formula powder, and respectively carries out adaptive design on aspects such as protein, fat, dietary fiber (prebiotics) and the like, and provides the infant formula powder containing breast milk oligosaccharide, which is suitable for infants of 0 to 3 years old, and can improve intestinal flora of infants and improve immunity.

According to a specific embodiment of the invention, the total protein content of the breast milk oligosaccharide-containing maternal emulsified infant formula powder is 10-19 g/100g, and the total protein mainly comprises milk protein. In addition, the proportion of whey protein to total protein is generally controlled to 38% to 70%. Specifically, the raw materials for providing the milk protein comprise one or more of basic raw materials of milk, whole milk powder, skimmed milk powder, whey protein powder and desalted whey powder; preferably, the breast milk oligosaccharide-containing breast milk infant formula powder comprises the following raw materials in parts by weight: 850-1750 parts of raw milk and 0-275 parts of skimmed milk powder, wherein the raw milk and the skimmed milk powder can be partially or completely replaced by equivalent whole milk powder and skimmed milk. Further, one or more of whey protein powder (such as whey protein powder WPC 80%, whey protein powder WPC 34%, and the like), desalted whey powder (such as desalted whey powder D70, D90, and the like) added for whey protein fortification, preferably including desalted whey powder, and whey protein powder (such as whey protein powder WPC 80% and/or whey protein powder WPC 34%); raw material alpha-lactalbumin powder is further added for the alpha-lactalbumin in the fortified product, and raw material beta-casein powder is further added for the beta-casein in the fortified product; preferably, the breast milk oligosaccharide-containing maternal emulsified infant formula powder comprises the following raw materials in parts by weight based on 1000 parts by weight: 0-170 parts of whey protein powder (preferably including 0-170 parts of whey protein powder WPC 34%); 25-225 parts by weight of desalted whey powder; 3-40 parts of alpha-lactalbumin powder; 0.5-25 parts of beta-casein powder.

In the breast milk oligosaccharide-containing breast milk infant formula powder, the raw material for providing fat may include vegetable oil in addition to the base raw material containing milk fat (such as the raw milk and the skim milk powder), the vegetable oil may include one or more of sunflower seed oil, corn oil, soybean oil, canola oil, coconut oil, palm oil and walnut oil, preferably includes sunflower seed oil, corn oil and soybean oil, and the addition of these vegetable oils provides fat components for the product on one hand, provides linoleic acid on the other hand, and also provides alpha-linolenic acid (preferably, the content of the alpha-linolenic acid in the milk powder of the present invention is 310 to 450mg/100 g). In addition, the raw material for providing the fat may optionally include a raw material OPO structural fat added for providing the 1, 3-dioleoyl-2-palmitic acid triglyceride. Because the raw materials of OPO structural fat sold in the market at present have different purities, namely the content of the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride is different and is usually about 40-70%, in the invention, in order to distinguish the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride and the raw materials thereof, the term "1, 3-dioleoyl-2-palmitic acid triglyceride" is adopted when describing the effective component, and the term "OPO structural fat" is adopted when describing the food raw material for providing the effective component 1, 3-dioleoyl-2-palmitic acid triglyceride. The specific addition amount of the OPO structural fat can be converted according to the content requirement of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the milk powder product and the purity of the OPO structural fat raw material. More preferably, the breast milk oligosaccharide-containing maternal emulsified infant formula powder comprises the following raw materials by weight based on 1000 parts of the breast milk oligosaccharide-containing maternal emulsified infant formula powder: 0-80 parts by weight of sunflower seed oil; 0-40 parts by weight of corn oil; 0-80 parts by weight of soybean oil; 0-140 parts of OPO structure grease.

Preferably, the contents of linoleic acid and alpha-linolenic acid in the sunflower seed oil, corn oil, soybean oil and OPO structure fat used as raw materials in the invention are respectively 7.6-8.9%, 0.25-0.38%, 53.0-56.20%, 0.9-1.6%, 50.0-53.5%, 7.6-9.6%, 5.9-6.3% and 0.4-0.62%, the contents of the canola oil linoleic acid and the alpha-linolenic acid used are respectively 16-19%, 8.0-10.6%, and the contents of the coconut oil linoleic acid and the alpha-linolenic acid are respectively 1-3% and 0-1%. The effective content of 1, 3-dioleic acid-2-palmitic acid triglyceride in the OPO structure fat raw material is 40-70%.

According to the specific embodiment of the invention, in the infant formula powder with the efficacy of improving the intestinal microenvironment health, the raw material for providing the breast milk oligosaccharide is directly from the commercialized breast milk oligosaccharide.

According to a specific embodiment of the present invention, the breast milk oligosaccharide-containing maternal emulsified infant formula of the present invention may further comprise a probiotic, preferably bifidobacteria. Preferably, the bifidobacterium is added in an amount of 0.1-0.2 parts by weight based on 1000 parts by weight of the breast milk oligosaccharide-containing breast emulsion infant formula powder; and more preferably 0.18 to 0.2 parts by weight. More preferably, the bifidobacterium powder contains 3 x 10 bifidobacteria per weight part¹⁰Above CFU.

According to a specific embodiment of the present invention, the breast milk oligosaccharide-containing maternal infant formula of the present invention, the carbohydrate is derived in part from lactose-containing base materials such as milk, whole milk powder and/or skim milk powder, and lactose materials should be additionally added to provide the carbohydrate. That is, in the infant formula powder of the present invention, the raw material for supplying carbohydrates includes lactose as a raw material in addition to the base material containing lactose. Preferably, the breast milk oligosaccharide-containing maternal emulsified infant formula powder comprises the following raw materials in parts by weight based on 1000 parts by weight of the maternal emulsified infant formula powder: 125-325 parts of lactose. The specific addition amount of lactose can be adjusted within the range, so that the carbohydrate content of the breast milk oligosaccharide-containing maternal emulsion infant formula powder of the invention is preferably 52-56 g/100 g.

According to a specific embodiment of the present invention, the raw materials of the breast milk oligosaccharide-containing breast milk infant formula powder of the present invention further include one or more of DHA, ARA, lactoferrin, and the like as appropriate, and further include a compound nutrient including calcium powder, vitamins, and minerals, and further include anhydrous cream and phospholipids as carriers used in spray drying in a milk powder preparation process. Preferably, the breast milk oligosaccharide-containing maternal emulsified infant formula powder comprises the following raw materials in parts by weight based on 1000 parts by weight of the maternal emulsified infant formula powder: 2-12 parts by weight of DHA; ARA 3-15 parts by weight; 8-16 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals; 1-4 parts by weight of phospholipid; 0-2 parts of anhydrous cream.

In the breast milk oligosaccharide-containing infant formula powder, the compound nutrient is a combination of nutrient components meeting the national standard, and different addition amounts are used according to different formulas. According to the formula powder, any one or any combination of the following compound nutrient components can be selectively adopted if the nutrient is added according to the needs. Preferably, the compound nutrient at least comprises compound vitamins, calcium powder and a mineral substance nutrient bag, and the dosage of each component is as follows:

1) compounding vitamins, wherein each gram of the compounding vitamins comprises the following components:

vitamin A: 1700 to 5800 mu gRE

Vitamin D: 30 to 70 μ g

Vitamin B1: 3600 to 6800 mu g

Vitamin B2: 3500 to 6900 mu g

Vitamin B6: 2400-4000 microgram

Vitamin B12: 8 to 20 μ g

Vitamin K1: 400 to 700 μ g

Vitamin C: 330-700 mg

Vitamin E: 27 to 70mg of alpha-TE

Nicotinamide: 26000-41550 μ g

Folic acid: 700 to 920 mu g

Biotin: 100 to 245 mu g

Pantothenic acid: 12000-25230 μ g

2) Mineral two, per gram of mineral two:

calcium: 300 to 455mg

Phosphorus: 75 to 150mg of

3) Minerals, per gram of mineral:

iron: 40-85 mg

Zinc: 23-48 mg

Copper: 2600-4180. mu.g

Iodine: 500 to 995 mu g

Selenium: 0 to 200 μ g

Manganese: 0 to 579 μ g

4) Magnesium chloride, per 1000 kg of milk powder:

magnesium: 80-170 g

5) Potassium chloride, per 1000 kg of milk powder:

potassium: 450 to 1000 g.

In addition, choline chloride (300-950 g of choline in every 1000 kg of milk powder) can be selectively contained in the compound nutrient, magnesium chloride (80-170 g of magnesium in every 1000 kg of milk powder) can be selectively contained in the compound nutrient, potassium chloride (450-1000 g of potassium in every 1000 kg of milk powder) can be selectively contained in the compound nutrient, and taurine (180-340 mg/g) can be selectively contained in the compound vitamin. The base material of the compound nutrient is preferably lactose. Preferably, based on 1000 parts by weight of the breast milk oligosaccharide-containing breast emulsion infant formula powder, the addition amount of the compound nutrient is 7-16 parts by weight, wherein the compound vitamin nutrient package is preferably 2-3 parts by weight, the calcium powder nutrient package is preferably 2-6 parts by weight, the mineral nutrient package is preferably 0.5-3 parts by weight, and the base material of each nutrient package is preferably lactose. The content of each component of the compound nutrient is the additive amount for enhancing the nutrient substance, and does not include the content of nutrient components in other raw materials of milk powder, for example, calcium powder (calcium carbonate), wherein each 1000 kg of milk powder contains' calcium: 1300-1600 g' refers to 1300-1600 g of calcium powder (such as calcium carbonate) added based on 1000 kg of milk powder for strengthening calcium element in the product.

In the breast milk oligosaccharide-containing breast milk infant formula powder, the raw material phospholipid and anhydrous cream are mainly used for forming powder particles in a spray drying process, and the phospholipid can be soybean phospholipid and/or lecithin. The usage amount of phospholipid and anhydrous butter is less, but the phospholipid and anhydrous butter also have certain contribution to the fat content in the milk powder product.

According to a preferred embodiment of the present invention, the present invention provides a breast milk oligosaccharide-containing maternal emulsion infant formula powder, which comprises the following raw materials:

7-16 parts by weight of compound nutrients comprising calcium powder, vitamins and minerals;

2-12 parts of DHA;

3-15 parts of ARA;

0.1-0.2 weight parts of bifidobacterium.

It can be understood that, in the breast milk oligosaccharide-containing breast milk infant formula powder of the present invention, the specific dosage of each raw material should be determined by adjusting on the premise of meeting the index requirements of the formula powder product. In the breast milk oligosaccharide-containing breast milk infant formula powder, product performance indexes which are not described or listed in detail are required to be executed according to national standards of infant formula food and regulations of related standards and regulations.

In the breast milk oligosaccharide-containing breast milk infant formula powder, all raw materials can be obtained commercially, and the selection of all raw materials meets the requirements of relevant standards, wherein the breast milk oligosaccharide simultaneously meets the requirements of the invention. In addition, the compound nutrient can also be compounded by self. "compounding" is used herein for convenience only and does not mean that the components of the formulation must be mixed together prior to use. All raw materials are added and used on the premise of meeting relevant regulations.

On the other hand, the invention also provides a method for preparing the breast milk oligosaccharide-containing breast milk infant formula powder, which adopts a wet or dry production process to mix breast milk oligosaccharide with other raw materials in the formula to prepare the infant formula powder. The preparation process mainly comprises the following steps: preparing materials, homogenizing, concentrating, sterilizing, spray drying, and dry mixing to obtain the final product. Specifically, the method for preparing the breast milk oligosaccharide-containing maternal emulsified infant formula powder comprises the following steps:

preparing materials: mixing raw milk and formula powder except spray carrier (phospholipid and anhydrous cream) and post-mixed material (such as DHA, ARA, lactoferrin, Bacillus bifidus, etc.) to obtain mixed material liquid;

homogenizing: homogenizing the mixed feed liquid;

concentration and sterilization: and (3) concentrating and sterilizing the homogenized feed liquid, wherein the concentrating and sterilizing conditions are as follows: double-effect concentration, wherein the sterilization temperature is more than or equal to 83 ℃, the sterilization time is 20-30 seconds, and the discharge concentration is controlled to be 48-52% of dry matter;

and (3) spray drying: preheating the concentrated milk to 60-70 ℃ by a scraper preheater, filtering the preheated material by a filter with the aperture of 0.8-1.2 mm, and then pumping the material into a drying tower for spray drying, wherein the spray drying conditions are controlled as follows: the air inlet temperature is 165-180 ℃, the air exhaust temperature is 75-90 ℃, the high-pressure pump pressure is 160-210 bar, and the tower negative pressure is-4 to-2 mbar;

fluidized bed drying and cooling: the powder coming out of the drying tower is dried for the second time by a primary fluidized bed, then is cooled to 25-30 ℃ by a secondary fluidized bed, and simultaneously, under the action of compressed air, the mixture of phospholipid (lecithin and/or soybean phospholipid) and carrier (anhydrous cream) heated to 60-65 ℃ is uniformly dispersed on the surface of the powder to obtain powder particles;

post-mixing: mixing the post-mixed material (DHA, ARA, lactoferrin, and Bacillus bifidus) with the fluidized bed dried and cooled powder particles, and packaging to obtain milk powder product.

According to the specific embodiment of the invention, the order of adding nutrients and the stirring and dissolving time are very important in the preparation method of the breast milk oligosaccharide-containing breast milk infant formula powder, preferably, calcium powder, vitamins and minerals are sequentially added into the mixed mixture of other powder materials and oil materials during the material preparation, the calcium powder is added, the mixture is stirred and dissolved for 15-25 minutes, the vitamins are added, the mixture is stirred and dissolved for 15-20 minutes, and the minerals are added, the mixture is stirred and dissolved for 15-20 minutes. The inventors have found in their studies that calcium powder is added first, and the calcium can be combined with casein in milk protein to form colloidal calcium, so that the precipitation of calcium can be avoided or reduced, but the combination process requires a sufficient time. Meanwhile, if calcium and minerals are added simultaneously, the calcium powder can adsorb part of the minerals such as iron to promote the minerals to change from ferrous iron to ferric iron, and the ferric iron is red, so that yellow to red precipitates are easily caused. And secondly, adding vitamins, wherein the vitamins comprise components such as VC which is easily oxidized by metal ions, and if minerals are added firstly, the vitamins are lost due to overhigh local vitamin concentration. And VC accelerates oxidation of ferrous iron if the local concentration is too high. The final addition of minerals is due to the fact that minerals disperse in water more slowly than vitamins, and during the dispersion process of minerals, water films are formed on the surfaces of particles to stabilize the minerals and do not damage milk proteins, and the process needs to be sufficient. The vitamin is fully mixed with the milk and diluted, and then the mineral is added, so that the loss of the vitamin by the mineral can be reduced.

According to a specific embodiment of the present invention, in the method for preparing a breast milk oligosaccharide-containing maternal emulsion infant formula powder, the ingredient process comprises:

milk rough filtration: after being subjected to coarse filtration and degassing by a balance cylinder, the milk is preheated by a plate heat exchanger, and then impurities are separated by a separator.

Homogenizing and sterilizing milk: one part of the raw milk without impurities enters a homogenizer for homogenization, the other part of the raw milk is inhomogeneous, and the homogenized raw milk are mixed and enter a sterilization system for sterilization.

Adding powder: various powder raw materials are metered according to the formula, uniformly added into a powder preparation tank through an air conveying system, and sucked into a vacuum mixing tank through a vacuum system;

dissolving and oil blending: putting the grease specified in the formula into an oil dissolving chamber according to the formula requirement, keeping the temperature of the oil dissolving chamber at 50-90 ℃, pouring the oil into a mixed oil storage tank after the oil is dissolved, and pouring the mixed oil into a material mixing tank through an oil pump according to the formula requirement;

dissolving and adding nutrients: respectively dissolving calcium powder, vitamins and minerals with purified water, and sequentially adding into a mixing tank to obtain mixed feed liquid.

In one embodiment of the present invention, the preparation method of the breast milk oligosaccharide-containing maternal emulsion infant formula powder of the present invention is performed as follows:

1) adding powder: various powder raw materials are metered according to the formula and then uniformly added into a powder preparation tank through an air conveying system for storage.

2) Vacuum powder absorption: various powder raw materials in the powder mixing tank are sucked into the vacuum mixing tank through a vacuum system.

3) Dissolving and oil blending: and (3) putting the grease specified in the formula into an oil dissolving chamber according to the formula requirement, keeping the temperature of the oil dissolving chamber at 50-90 ℃, and pumping the oil into a mixed oil storage tank according to the formula proportion requirement through an oil pump and a flowmeter after the oil is dissolved.

4) Storing the mixed oil material: and (3) storing the mixed oil in an oil storage tank in a heat-preservation way at the temperature of 40-50 ℃ for less than 12 hours to prevent fat oxidation.

5) Weighing: and pumping the mixed oil into a mixing tank through an oil pump according to the formula requirement.

6) Dissolving and adding nutrients: respectively adding calcium powder, mineral substances, vitamins and the like, respectively dissolving the calcium powder, the mineral substances, the vitamins and the like by using 100-200 kg of purified water, and then pumping the mixture into a wet mixing cylinder, wherein each time the mixture is beaten, the adding tank and the pipeline are flushed by using 100kg of purified water.

7) And (3) filtering: filtering the mixed feed liquid by a filter screen to remove physical impurities possibly brought in the raw materials.

8) Homogenizing: homogenizing the mixed material liquid with homogenizer at first stage pressure of 105 + -5 bar and first stage pressure of 32 + -3 bar, mechanically processing the fat globules, and dispersing them into uniform fat globules.

9) Cooling and storing: and (3) feeding the homogenized material liquid into a plate heat exchanger for cooling: cooling to below 20 ℃, temporarily storing in a pre-storage cylinder, entering the next procedure within 6 hours, and starting the stirrer according to the set requirement.

10) Concentration and sterilization: double-effect concentration is adopted during production, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds. The discharged material concentration is 48-52% dry matter.

11) Storing concentrated milk, preheating, filtering and spray drying: the concentrated milk is temporarily stored in a concentrated milk balancing tank. Preheating to 60-70 ℃ by a scraper preheater, filtering the preheated material by a filter with the aperture of 1mm, pumping the filtered material into a drying tower by a high-pressure pump for spray drying, and agglomerating fine powder on the tower top or a fluidized bed as required. Air inlet temperature: 165-180 ℃, the exhaust temperature is 75-90 ℃, the high-pressure pump pressure is 160-210 bar, and the tower negative pressure is-4 to-2 mbar.

12) Drying and cooling the fluidized bed: and (3) drying the powder discharged from the drying tower for the second time by using a fluidized bed (first stage), and cooling to 25-30 ℃ by using a fluidized bed (second stage). Meanwhile, phospholipid and a carrier are mixed and heated to 60-65 ℃, and are uniformly dispersed on the surface of the powder under the action of compressed air, so that the particle size and the instant solubility of the powder particles are increased by agglomeration.

13) Subpackaging: and (3) weighing, bagging and subpackaging DHA, ARA lactoferrin and bifidobacterium by powder making workshop personnel according to the formula requirements.

14) Dry mixing: and uniformly mixing the weighed post-mixed materials (DHA, ARA, lactoferrin and bifidobacterium) and the milk powder in a dry mixer.

15) Powder sieving: the granularity of the milk powder is uniform through the vibrating screen, and the powder residue is discarded.

16) Powder discharging: and (4) receiving the powder by using a sterilized powder collecting box, and conveying the powder to a powder feeding room from a powder discharging room.

17) Powdering: pouring the milk powder into a powder storage tank on a large and small packaging machine according to the packaging requirements.

18) Packaging: 400 g of the mixture is packaged by an automatic packaging machine in a nitrogen-filled mode. The oxygen content is lower than 1% when charging nitrogen. The oxygen content of the 900 g iron can in the automatic nitrogen-filled package is lower than 5 percent.

19) Boxing: and (4) filling the packaged small bags into a paper box, adding a powder spoon, and sealing by using a box sealing machine.

20) And (4) inspecting a finished product: and sampling and inspecting the packaged product according to an inspection plan.

21) And (4) warehousing and storing: and warehousing and storing the qualified product at normal temperature with the humidity less than or equal to 65 percent.

In the invention, the breast milk oligosaccharide can be mixed together during the compounding process, and can also be added in the post-mixing process.

On the other hand, the invention also provides application of the infant formula powder in preparing food with the effect of improving the intestinal microenvironment health. Wherein the improving intestinal microenvironment health comprises: regulate butyric acid production in the gut system, increase the overall production of short chain fatty acids, be utilized by the gut flora as prebiotics in the gut system and produce gas, reduce the production of isobutyric acid and/or isovaleric acid, and/or lower pH to maintain healthy gut microenvironment.

According to a specific embodiment of the invention, in the infant formula powder with the efficacy of improving the intestinal microenvironment health, the breast milk oligosaccharide is fucosyl oligosaccharide, sialyl oligosaccharide or lacto-N-tetraose. Preferably, the fucosyl oligosaccharide is 2' -FL and/or 3-FL and the sialyl oligosaccharide is 3-SL and/or 6-SL.

According to some embodiments of the invention, the breast milk oligosaccharide in the infant formula of the invention is for regulating butyrate production in the proximal colon, said breast milk oligosaccharide being 6-SL. Under the application, the application amount of 6-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L in terms of conversion into milk; preferably 70.9-606.1mg/100g powder, or 0.1-0.8g/L calculated by conversion into milk; more preferably 70.9 to 454.6mg/100g of the powder, or 0.1 to 0.6g/L in terms of milk.

According to some embodiments of the invention, the breast milk oligosaccharides in the infant formula of the invention are for regulating butyrate production in the distal colon, said breast milk oligosaccharides being 3-SL and/or 6-SL. Preferably, the breast milk oligosaccharide is further used for reducing the production of isobutyric acid and/or isovaleric acid in the distal colon, in this application the breast milk oligosaccharide is further preferably 3-SL. The application amount of 3-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L calculated by converting into milk; preferably 70.9-454.6mg/100g powder, or 0.1-0.6g/L calculated by conversion into milk; more preferably 70.9 to 227.3mg/100g of the powder, or 0.1 to 0.3g/L in terms of milk. The application amount of 6-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L calculated by converting into milk; preferably 70.9-606.1mg/100g powder, or 0.1-0.8g/L calculated by conversion into milk; more preferably 70.9 to 454.6mg/100g of the powder, or 0.1 to 0.6g/L in terms of milk.

According to some embodiments of the invention, the breast milk oligosaccharides in the infant formula of the invention are for use by the gut flora as prebiotics in the proximal colon and produce gas, said breast milk oligosaccharides being 3-SL and/or 6-SL. The application amount of 3-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L calculated by converting into milk; preferably 70.9-454.6mg/100g powder, or 0.1-0.6g/L calculated by conversion into milk; more preferably 70.9 to 227.3mg/100g of the powder, or 0.1 to 0.3g/L in terms of milk. The application amount of 6-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L in terms of conversion into milk; preferably 70.9-606.1mg/100g powder, or 0.1-0.8g/L calculated by conversion into milk; more preferably 70.9 to 454.6mg/100g of the powder, or 0.1 to 0.6g/L in terms of milk.

According to some embodiments of the invention, the breast milk oligosaccharides in the infant formula of the invention are for increasing the overall production of short chain fatty acids in the proximal and/or distal colon, said breast milk oligosaccharides being 3-SL and/or 6-SL. Under the application, the application amount of the 3-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L in terms of conversion into milk; preferably 70.9-454.6mg/100g powder, or 0.1-0.6g/L calculated by conversion into milk; more preferably 70.9 to 227.3mg/100g of the powder, or 0.1 to 0.3g/L in terms of milk. The application amount of 6-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L in terms of conversion into milk; preferably 70.9-606.1mg/100g powder, or 0.1-0.8g/L calculated by conversion into milk; more preferably 70.9 to 454.6mg/100g of the powder, or 0.1 to 0.6g/L in terms of milk.

According to some embodiments of the invention, the breast milk oligosaccharides in the infant formula of the invention are used to lower the proximal colonic pH to maintain a healthy intestinal microenvironment. The breast milk oligosaccharide is 3-SL and/or 6-SL. Under the application condition, the application amount of the 3-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L in terms of conversion into milk; preferably 70.9-454.6mg/100g powder, or 0.1-0.6g/L calculated by conversion into milk; more preferably 70.9 to 227.3mg/100g of the powder, or 0.1 to 0.3g/L in terms of milk. The application amount of 6-SL in the milk powder is 14.2-1515.3mg/100g of powder, or 0.02-2.0g/L calculated by converting into milk; preferably 70.9-606.1mg/100g powder, or 0.1-0.8g/L calculated by conversion into milk; more preferably 70.9 to 454.6mg/100g of the powder, or 0.1 to 0.6g/L in terms of milk.

According to some embodiments of the present invention, the breast milk oligosaccharides in the infant formula of the present invention also contribute to the production of short chain fatty acids, such as formic acid, propionic acid, acetic acid, etc., in the intestinal system, which are beneficial to the human body.

In conclusion, the invention discovers that the breast milk oligosaccharide can obviously improve the intestinal microenvironment health, and the infant formula powder is closer to breast milk when being added into the infant formula powder, can regulate and control the generation of butyric acid, improves the intestinal microenvironment health and has wide application prospect.

Drawings

FIG. 1A is a schematic representation of fecal inoculation culture in the SHIME device of the present invention.

FIG. 1B shows a schematic representation of the SHIME fermentation package of the present invention.

Figure 2 shows the simulated bacterial flora of the proximal (left) and distal (right) colon after two weeks of culture in a SHIME device simulating the colon of an infant.

FIG. 3A shows the results of pH measurements of the proximal colon over time for each HMO of the present invention in a small batch fermentation experiment.

FIG. 3B shows the results of pH measurements of distal colon over time for each HMO of the invention in a small batch fermentation experiment.

FIG. 4A shows the time-dependent measurements of proximal colon induced air pressure for various HMOs of the present invention in a small batch fermentation experiment.

FIG. 4B shows the results of measurements of the time-dependent changes in distal colon-induced air pressure for each HMO of the present invention in a small batch fermentation experiment.

FIG. 5 shows the overall results of the present invention for simulating the production of short chain fatty acids by small batch fermentation of individual HMOs in the proximal colonic environment.

FIG. 6 shows the results of the detection of butyric acid produced in a fecal batch fermentation experiment in which each monomer of breast milk oligosaccharide mimics the proximal colon of an infant in accordance with the present invention.

FIG. 7 shows the results of formic acid detection in stool batch fermentation experiments in which individual human milk oligosaccharides mimic the proximal colon of infants.

FIG. 8 shows the results of the detection of acetic acid produced in stool batch fermentation experiments in which individual human milk oligosaccharides mimic the proximal colon of infants in accordance with the present invention.

FIG. 9 shows the results of propionic acid production in stool batch fermentation experiments in which individual human milk oligosaccharides mimic the proximal colon of infants in accordance with the present invention.

FIG. 10 shows the overall results of short chain fatty acids generated in fecal batch fermentation experiments in which each monomer of breast milk oligosaccharides mimics distal colon of infants according to the present invention.

FIG. 11 shows the results of the detection of butyric acid produced in the fecal batch fermentation experiment in which each monomer of breast milk oligosaccharide mimics the distal colon of an infant in the present invention.

FIG. 12 shows the results of formic acid detection in stool batch fermentation experiments in which individual human milk oligosaccharides mimic the distal colon of an infant in accordance with the present invention.

FIG. 13 shows the results of the detection of acetic acid produced in stool batch fermentation experiments in which individual human milk oligosaccharides mimic the distal colon of an infant in accordance with the present invention.

FIG. 14 shows the results of propionic acid production in stool batch fermentation experiments in which individual human milk oligosaccharides mimic the distal colon of infants in accordance with the present invention.

FIGS. 15A and 15B show the results of the fermentation of isobutyric acid and isovaleric acid from stool batch experiments in which individual human milk oligosaccharides mimic the distal colon of an infant in accordance with the present invention.

Detailed Description

For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description taken in conjunction with the accompanying specific embodiments, and the technical solutions of the present invention are described, it being understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.

In the examples, each raw reagent material is commercially available, and the experimental method not specifying the specific conditions is a conventional method and a conventional condition well known in the art, or a condition recommended by an instrument manufacturer.

Example 1

Breast milk oligosaccharide-containing breast milk infant formula (1000 kg prepared):

1000 kg of milk, 300 kg of lactose, 40 kg of whey protein powder WPC 80%, 90D 90175 kg of desalted whey powder, 30 kg of sunflower seed oil, 20 kg of corn oil, 65 kg of soybean oil, 110 kg of OPO structural fat, 27 kg of alpha-whey protein powder, 9 kg of beta-casein powder, 2 kg of lecithin, 1 kg of anhydrous cream, 17 kg of fructo-oligosaccharide powder, 40 kg of galacto-oligosaccharide syrup, 1 kg of breast milk oligosaccharide (HMO), 14.35 kg of compound nutrient, 8 kg of DHA, 8 kg of ARA and 0.2 kg of bifidobacterium.

Wherein 1 kg of breast milk oligosaccharide (HMO) is 3-SL or 6-SL.

The compound nutrients comprise a compound vitamin nutrient bag of about 2.5 kg, a choline chloride nutrient bag of about 0.75 kg, a calcium powder nutrient bag of about 6 kg, a mineral nutrient bag of about 1 kg and a magnesium chloride and potassium chloride nutrient bag, wherein the base material of each nutrient bag is lactose, and the specific main nutrients comprise the following components: 1) compounding vitamins, wherein in each gram of the compounding vitamins, taurine: 180 mg; vitamin a (retinyl acetate): 2300 μ gRE; vitamin D (cholecalciferol): 34 mu g of the total weight of the mixture; vitamin B1 (thiamine nitrate): 4000 microgram; vitamin B2 (riboflavin): 1200 mug; vitamin B6 (pyridoxine hydrochloride): 2050 μ g; vitamin B12 (cyanocobalamin): 11.2 mu g; vitamin K1 (phytomenadione): 400 mu g; vitamin C (L-ascorbic acid): 495 mg; vitamin E (dl- α -tocopheryl acetate): 38mg of alpha-TE; nicotinamide: 23050 μ g; folic acid: 530 μ g; biotin (D-biotin): 88 mu g of the total weight of the mixture; pantothenic acid (calcium D-pantothenate): 15000 mu g; 2) calcium powder, per gram of calcium powder, calcium (calcium carbonate, tricalcium phosphate): 230 mg; phosphorus (tricalcium phosphate): 90 mg; 3) minerals, per gram of mineral, iron (ferrous sulfate): 80 mg; zinc (zinc sulfate): 45 mg; copper (copper sulfate): 4000 microgram; iodine (potassium iodide): 980 ug; selenium (sodium selenite): 170 mu g of the mixture; manganese (manganese sulfate): 550 mu g of the solution; 4) magnesium chloride, per 1000 kg of milk powder, magnesium (magnesium chloride): 150g of the total weight of the mixture; 5) potassium chloride, per 1000 kg of milk powder, potassium (potassium chloride): 1050g of the total weight of the mixture; 6) choline chloride, per 1000 kg of milk powder, choline (choline chloride): 700 g.

Wherein the contents of linoleic acid and alpha-linolenic acid in the used raw materials of high oleic acid sunflower seed oil, corn oil, soybean oil and structured oil (OPO) are respectively 8.20%, 0.3%, 55.50%, 1.2%, 52.10%, 8.8%, 6.18% and 0.47%.

The preparation process of the breast milk oligosaccharide-containing breast milk infant formula milk powder comprises the following steps:

3) Dissolving and oil blending: the grease specified in the formula is put into the oil-dissolving room according to the formula requirement, the temperature of the oil-dissolving room is kept at 60 ℃, and after the oil is dissolved, the oil is pumped into a mixed oil storage tank through an oil pump and a flowmeter according to the formula proportion requirement.

4) Weighing: the mixed oil is pumped into a mixing tank through an oil pump according to the formula requirement.

5) Dissolving and adding nutrients: calcium powder, mineral substances, vitamins and the like are respectively added, 150kg of purified water is respectively used for dissolving, then the materials are thrown into a material mixing tank, and after each time of throwing, the adding tank and the pipeline are washed by 100kg of purified water.

6) And (3) filtering: filtering the mixed feed liquid by a filter screen to remove physical impurities possibly brought in the raw materials.

7) Homogenizing: homogenizing the mixed material liquid by a homogenizer, mechanically processing the fat balls, and dispersing the fat balls into uniform fat balls.

8) Cooling and storing: and (3) feeding the homogenized material liquid into a plate heat exchanger for cooling: cooling to below 20 ℃, temporarily storing in a pre-storing cylinder, entering the next procedure within 6 hours, and starting the stirrer according to the set requirement.

9) Concentration and sterilization: double-effect concentration is adopted during production, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds. The discharge concentration was 50% dry matter.

10) Storing concentrated milk, preheating, filtering and spray drying: the concentrated milk is temporarily stored in a concentrated milk balancing tank. Preheating to 60 deg.C with a scraper preheater, filtering the preheated material with a filter with 1mm pore diameter, pumping into a drying tower with a high pressure pump, spray drying, and agglomerating fine powder at the tower top or fluidized bed as required. Air inlet temperature: 180 ℃, the exhaust temperature is 86 ℃, the pressure of the high-pressure pump is 200bar, and the negative pressure of the tower is about-4 mba.

11) Drying and cooling the fluidized bed: the powder from the drying tower is dried by the fluidized bed (first stage) for the second time, and then cooled to 30 ℃ by the fluidized bed (second stage). Meanwhile, lecithin and a carrier are mixed and heated to 60 ℃, and the mixture is uniformly dispersed on the surface of the powder under the action of compressed air, so that the particle size and the instant solubility of the powder are increased by agglomeration of the powder particles.

12) Subpackaging: and (3) weighing DHA, ARA or bifidobacterium, sealing bags and subpackaging according to the formula requirements by powder-making workshop personnel.

13) Dry mixing: and uniformly mixing the weighed DHA, ARA or bifidobacteria with the milk powder in a dry mixer.

14) Powder sieving: the granularity of the milk powder is uniform through the vibrating screen, and the powder residue is discarded.

15) Powder discharging: and (4) receiving the powder by using a sterilized powder collecting box, and conveying the powder to a powder feeding room from a powder discharging room.

16) Powdering: pouring the milk powder into a powder storage tank on a large and small packaging machine according to the packaging requirements.

17) Packaging: 400 g of the mixture is packaged by an automatic packaging machine in a nitrogen-filled mode. The oxygen content is lower than 1% when charging nitrogen. The oxygen content of the 900 g iron can automatic nitrogen-filled package is lower than 5 percent.

18) Boxing: and (4) filling the packaged small bags into a paper box, adding a powder spoon, and sealing by using a box sealing machine.

19) And (4) inspecting a finished product: and sampling and inspecting the packaged product according to an inspection plan.

20) And (4) warehousing and storing: and warehousing and storing the qualified product at normal temperature with the humidity less than or equal to 65 percent.

Example 2

1200 kg of milk, 140 kg of lactose, 100kg of whole milk powder, 260 kg of skim milk powder, 100% of whey protein powder WPC34, 90210 kg of desalted whey powder D, 22 kg of sunflower seed oil, 15 kg of corn oil, 48 kg of soybean oil, 85 kg of OPO structural lipid, 4 kg of alpha-whey protein powder, 1 kg of beta-casein powder, 2 kg of soybean lecithin, 1 kg of anhydrous cream, 5 kg of fructo-oligosaccharide powder, 13 kg of galacto-oligosaccharide syrup, 1.2 kg of breast milk oligosaccharide (HMO), 10.3 kg of compound nutrient, 7 kg of DHA, 8 kg of ARA and 0.18 kg of bifidobacterium.

Wherein 1.2 kg of breast milk oligosaccharide (HMO) is 3-SL or 6-SL.

The compound nutrients comprise a compound vitamin nutrient bag of about 2.6 kg, a choline chloride nutrient bag of about 0.35 kg, a calcium powder nutrient bag of about 3.7 kg, a mineral nutrient bag of about 1.3 kg and a magnesium chloride and potassium chloride nutrient bag, wherein the base material of each nutrient bag is lactose, and the specific main nutrients comprise the following components: 1) compounding vitamins, wherein in each gram of the compounding vitamins, taurine: 190 mg; vitamin a (retinyl acetate): 2000. mu.gRE; vitamin D (cholecalciferol): 40 mu g of the mixture; vitamin B1 (thiamine nitrate): 3900 mu g; vitamin B2 (riboflavin): 1000 μ g; vitamin B6 (pyridoxine hydrochloride): 1500 ug; vitamin B12 (cyanocobalamin): 5 mu g of the solution; vitamin K1 (phytomenadione): 350 mu g; vitamin C (L-ascorbic acid): 400 mg; vitamin E (dl- α -tocopheryl acetate): 30mg of alpha-TE; nicotinamide: 23000 μ g; folic acid: 420 mu g of the total weight of the mixture; biotin (D-biotin): 70 mu g of the solution; pantothenic acid (calcium D-pantothenate): 8000 mug; 2) calcium powder, per gram of calcium powder, calcium (calcium carbonate, tricalcium phosphate): 250 mg; phosphorus (tricalcium phosphate): 75 mg; 3) minerals, per gram of mineral, iron (ferrous sulfate): 76 mg; zinc (zinc sulfate): 26 mg; copper (copper sulfate): 2700 ug; iodine (potassium iodide): 600 mu g; selenium (sodium selenite): 160 mu g; 4) magnesium chloride, per 1000 kg of milk powder, magnesium (magnesium chloride): 85 g; 5) potassium chloride, per 1000 kg of milk powder, potassium (potassium chloride): 1000 g; 6) choline chloride, per 1000 kg of milk powder, choline (choline chloride): 700 g.

Wherein the contents of linoleic acid and alpha-linolenic acid in the sunflower seed oil, corn oil, soybean oil and structured oil (OPO) are respectively 8.20%, 0.3%, 55.50%, 1.2%, 52.10%, 8.8%, 6.18% and 0.47%.

The preparation process of the breast milk oligosaccharide (HMO) -containing maternal emulsified infant formula milk powder comprises the following steps:

3) Dissolving and oil blending: the grease specified in the formula is put into an oil dissolving room according to the formula requirement, the temperature of the oil dissolving room is kept at 60 ℃, and after the oil is dissolved, the oil is pumped into a mixed oil storage tank through an oil pump and a flowmeter according to the formula proportion requirement.

9) Concentration and sterilization: double-effect concentration is used during production, the sterilization temperature is more than or equal to 83 ℃, and the sterilization time is 25 seconds. The discharge concentration was 50% dry matter.

11) Drying and cooling the fluidized bed: the powder from the drying tower is dried for the second time by the fluidized bed (first stage) and then cooled to 30 ℃ by the fluidized bed (second stage). Meanwhile, the soybean lecithin and the carrier are mixed and heated to 60 ℃, and are uniformly dispersed on the surface of the powder under the action of compressed air, so that the particle size and the instant solubility of the powder are increased by agglomeration.

12) Subpackaging: and (3) weighing DHA, ARA or bifidobacterium, sealing bags and subpackaging by powder-making workshop personnel according to the formula requirements.

16) Powdering: pouring the milk powder into a powder storage tank on a large and small packing machine according to the packing requirement.

17) Packaging: 400 g of the mixture is packaged by an automatic packaging machine in a nitrogen-filled mode. The oxygen content is lower than 1% when charging nitrogen. The oxygen content of the 900 g iron can in the automatic nitrogen-filled package is lower than 5 percent.

Experiment on the efficacy of oligosaccharide in breast milk

Fecal inoculation culture in SHIME devices

Using a SHIME device (see schematic FIG. 1A), a flora-containing infant was obtained from a natural delivery at 5 months of age and a healthy infant who had received breast feeding onlyAnd inoculated into containers corresponding to the proximal and distal colon. Food was fed to the stomach/small intestine end of the device three times a day for two weeks to support growth and colonization of the flora in the proximal and distal colon. Wherein the food material digested from the small intestine and delivered to the colon is prepared by adjusting the ratio of lactose, casein and whey protein based on the standard food material provided by ProDiget, a producer of SHIME device, the standard food material consisting of the following components: pectin (1g/L), glucose (1g/L), starch (1g/L), cellobiose (1g/L),

peptone (2g/L), mucin (6g/L), lactose (2.1g/L), casein (0.2g/L), lactalbumin-lactalbumin (2.7g/L), L-cysteine hydrochloride (0.2 g/L). The food material in each experiment of the invention, referred to Le Blay et al (2010), adjusted the ratio of lactose, casein and whey protein to be about 12:1:15 and ensured a stable and balanced nutrient to simulate the food composition that the intestinal micro-ecology of infants may contact under the condition of conventional breast milk or infant formula feeding. After two weeks of stabilization of the infant fecal flora in the SHIME model, the proximal and distal colon were sampled, dissolved in glycerol to form a stock solution, and stored under anaerobic conditions at-80 ℃.

Analytical testing of microbiota composition will focus on specific strains: lactobacilli, bifidobacteria, rosella, eubacteria and coprobacteria, as they are known to be associated with (prebiotic) health efficacy. The detection assay is based on qPCR.

Small batch fermentation

After the infant flora was inoculated into the SHIME model and grown for 2 weeks stably (as described in the aforementioned "feces inoculation culture in SHIME device"), 10mL of the flora from the proximal and distal colon were taken and transferred to fermentation flasks for small batch fermentation under anaerobic conditions. Each flask contained 20mL PBS buffer (for dissolution and entrainment of HMO test substances) with different levels of HMO based on 43mL base buffer (for pH adjustment and simulation of the corresponding colonic environment) to give final concentrations of 0.02g/L, 0.2g/L, 2g/L of each HMO, a proximal colonic pH of 5.6 and a distal colonic pH of 6.5. The vials were incubated at 37 ℃ with shaking. At the time of incubation, air pressure was measured at 0, 6, 24 and 48 hours, followed by sampling to measure pH and short chain fatty acids. The assay was repeated three times.

During HMO intervention, the gas production of each group was compared by measuring the pressure change. Analysis of short chain fatty acids included isobutyric acid, isovaleric acid, butyric acid, propionic acid and acetic acid, as well as formic acid, each of which was analyzed by HPLC.

SHIME fermentation

The stored infant fecal flora was sampled and inoculated into the SHIME model using the "feces inoculation culture in SHIME device" to investigate HMO fermentation in the SHIME device. Two experiments were performed before and after, each with three sample groups (or controls) simultaneously. Of the three experimental sets, the devices simulating the extreme and distal colon were inoculated separately (see schematic in FIG. 1B). The diet was fed three times a day and after 4 days of culture, HMO was added to the diet fed (no HMO was added to the control group). For each diet, 280mg of HMO (2g/L concentration) and 60mL of pancreatic juice were added to 140mL of the diet. Each HMO and control group was subjected to only 1 experiment, and thus the biological repetition was 1. SHIME fermentation was continued until day 14 after HMO intervention, with sampling at various time periods during fermentation.

Data analysis

A two-sample two-sided T-test (two tailed, paired T-test) was performed on the data results. Two groups were marked with an asterisk if they were significantly different and p < 0.05. Two asterisks indicate p < 0.01. Three asterisks indicate p < 0.001.

Simulating flora conditions in proximal and distal colonic environments

For the identification of the fecal flora two weeks after stable inoculation and culture in the SHIME device, see FIG. 2. After two weeks of stabilization in the SHIME model, the bifidobacteria and lactobacilli were found to be very low and hardly detectable by flora determination, consistent with previous reports (Laforemost-Lamopine, 2017). It was demonstrated that the flora environment corresponding to the colon tended to be more likely to be formula fed infants than breast fed infants after feeding with a standard food stuff containing lactose/casein/whey in a simulated infant intestinal environment.

pH changes over time for each HMO in the Small batch fermentation experiments

The results of the time-dependent pH measurements of the proximal colon for each HMO in the small batch fermentation experiments are shown in fig. 3A. The results of the time-dependent pH measurements of the distal colon for each HMO in the small batch fermentation experiments are shown in fig. 3B. It can be seen that the pH decrease over 6 hours is more pronounced in the proximal colon than at other time points. It can be seen that as the fermentation time is prolonged, HMO is utilized by the flora in the infant faeces to produce short chain fatty acids, thereby lowering the pH.

Air pressure changes over time for each HMO in the small batch fermentation experiments

The results of measurements of the time-dependent changes in proximal colon-induced air pressure for each HMO in the small batch fermentation experiments are shown in fig. 4A. The results of the time dependent changes in air pressure induced by the distal colon for each HMO in the small batch fermentation experiments are shown in fig. 4B. It can be seen that the oligosaccharide of the two sialic acids 3-SL and 6-SL produced higher air pressure in the proximal colon at 2g/L, which demonstrates that the two oligosaccharides are better utilized by the fecal flora under these conditions. Whereas all HMOs at 2g/L resulted in an increase in gas pressure under conditions simulating the distal colon.

Simulating the condition of short-chain fatty acid produced by small-batch fermentation of various HMOs in the environment of the near-end colon

Results of measurements of the total amount of short chain fatty acids produced by small batch fermentation of individual HMOs in simulated proximal colon environment are shown in fig. 5. It can be seen that after 48 hours of fermentation for all HMOs the short chain fatty acids produced were higher relative to the other time points, in particular 3-SL and 6-SL produced significantly more SCFA at 2g/L, with 2g/L of 3-SL also producing more SCFA after 24 hours of fermentation.

The results of the detection of butyric acid production by HMOs in small batch fermentation in simulated proximal colon environment are shown in fig. 6. It can be seen that only 6-SL, in a simulated proximal colon environment, significantly increased butyric acid production after 48 hours of fermentation.

The results of the detection of formic acid production by HMOs in small batch fermentation in a simulated proximal colon environment are shown in fig. 7. It can be seen that only 3-SL and 6-SL significantly increased formic acid after 48 hours of fermentation in the simulated proximal colon. With the 6-SL effect being more pronounced.

The results of the detection of acetic acid production by various HMOs in small batch fermentation in a simulated proximal colon environment are shown in fig. 8. It can be seen that only 3-SL and 6-SL significantly increased acetic acid after 48 hours of simulated proximal colon fermentation. With the 3-SL effect being more pronounced.

The results of the detection of propionic acid production by HMOs in small batch fermentation in a simulated proximal colon environment are shown in figure 9. It can be seen that only 6-SL significantly increased propionic acid after 48 hours of simulated proximal colon fermentation.

Simulating the condition of short-chain fatty acid produced by small-batch fermentation of various HMOs in the environment of the far-end colon

Results of measurements of the total amount of short chain fatty acids produced by small batch fermentation of individual HMOs in simulated distal colonic environment are shown in fig. 10. It can be seen that in the distal colon, each HMO is more active in producing SCFA than in the proximal colon, which also supports the accepted scientific view that most of the fermentation of the intestinal flora occurs in the distal colon. The SCFA produced increased with time from 0, 6, 24, to 48 hours. At this 6 hour time point, 0.02g/L of 3-SL and 0.02g/L of LNT produced relatively more short chain fatty acids; at this time point of 24 hours, 2g/L of 6-SL and 2g/L of 3-FL produced relatively more short-chain fatty acids; at this time point of 48 hours, all HMOs produced more short chain fatty acids at 2 g/L.

The results of the detection of butyric acid production by HMOs in small-scale fermentation in a simulated distal colonic environment are shown in fig. 11. It can be seen that only 3-SL and 6-SL significantly increased butyrate after 48 hours of fermentation in the simulated distal colon.

The results of the detection of formic acid production by HMOs in small batch fermentation in a simulated distal colon environment are shown in fig. 12. It can be seen that all HMOs significantly increased formic acid after 48 hours of simulated distal colonic fermentation. Wherein the effect is more remarkable with 3-SL, 6-SL, LNT and 3-FL.

The results of the detection of acetic acid production by HMOs in small batch fermentation in a simulated distal colon environment are shown in fig. 13. It can be seen that all HMOs significantly increased acetic acid after 48 hours of simulated distal colonic fermentation. Of which the effect is more pronounced with 3-SL, 6-SL and LNT.

The results of the detection of propionic acid production by HMOs in small batch fermentation in a simulated distal colon environment are shown in fig. 14. It can be seen that all HMOs significantly increased propionic acid after 48 hours of simulated distal colonic fermentation. With the effect being more pronounced with 3-SL and 3-FL.

The results of the detection of isobutyric acid and isovaleric acid production from various HMOs in small-scale fermentations in simulated distal colon environments are shown in fig. 15A and 15B, respectively. It can be seen that in the distal colon, 2' -FL, 3-FL and 3-SL, LNT all significantly reduced the production of isobutyric acid. The two sialic acid oligosaccharides and the two fucosyl oligosaccharides can respectively reduce the generation of isovaleric acid.

Simulating the condition that each HMO produces butyric acid by fermentation in the SHIME model under the environment of the far-end colon

The results of the detection of butyric acid production by HMOs in the SHIME model fermentation in the simulated distal colon environment are shown in table 1.

TABLE 1

In the case of SHIME model fermentation, after 14 days of fermentation, butyric acid production by various HMOs was reduced compared to initial day 1, but by the most fold compared to the control (without HMO); compared with the reduction factor of the 1 st day, the HMO dry prognosis has obvious improvement and improvement on the 14 th day, wherein the reduction factor of the 3-SL is the lowest, and the 3-FL is the second day, and the 6-SL, the 2' -FL and the LNT have better improvement effect compared with a control. Therefore, the regulation and control of each HMO on butyric acid in the fermentation product have certain advantages compared with a control group without HMO.

Claims

1. The application of the breast milk oligosaccharide in preparing the infant formula powder for improving the intestinal microenvironment health, wherein the breast milk oligosaccharide is fucosyl oligosaccharide, sialyl oligosaccharide or lacto-N-tetraose; the improving the intestinal microenvironment health comprises: regulate production of butyric acid in the gut system, increase overall production of short chain fatty acids, be utilized by the gut flora as prebiotics in the gut system and produce gas, reduce production of isobutyric acid and/or isovaleric acid, and/or lower pH to maintain intestinal microenvironment health.

2. An infant formula powder with the effect of improving intestinal microenvironment health comprises breast milk oligosaccharide, wherein the breast milk oligosaccharide is fucosyl oligosaccharide, sialyl oligosaccharide or lacto-N-tetraose; the improving the intestinal microenvironment health comprises: regulate production of butyric acid in the gut system, increase overall production of short chain fatty acids, be utilized by the gut flora as prebiotics in the gut system and produce gas, reduce production of isobutyric acid and/or isovaleric acid, and/or lower pH to maintain intestinal microenvironment health.

3. The infant formula of claim 2, wherein the infant formula comprises 14.2-1515.3mg/100g of breast milk oligosaccharide, or 0.02-2.0g/L of breast milk oligosaccharide based on milk.

4. The infant formula powder according to claim 2, wherein the infant formula powder contains 14.2-1515.3mg/100g of breast milk oligosaccharides, the total protein content of the infant formula powder is 10-19 g/100g, the whey protein accounts for 38-70% of the total protein, the alpha-lactalbumin content is 1.25-2.5 g/100g, the beta-casein content is 2.2-4.0 g/100g, the fat content is 17-29 g/100g, the linoleic acid content is 2500-4500 mg/100g, the alpha-linolenic acid content is 330-450 mg/100g, the dietary fibers are 0.95-6.3 g/100g, the dietary fibers comprise galactooligosaccharides, fructooligosaccharides and/or breast milk oligosaccharides, and the carbohydrate content is 50-57 g/100 g.

5. The infant formula of claim 2 or 3 or 4, wherein the breast milk oligosaccharide is 3-SL and/or 6-SL.

6. The method for preparing the infant formula powder according to any one of claims 2 to 5, wherein the infant formula powder is prepared by mixing breast milk oligosaccharides with other raw materials in a formula by a wet or dry production process.

7. Use of the infant formula powder of any one of claims 2-5 in the preparation of an infant formula for improving gut microenvironment health, wherein the improving gut microenvironment health comprises: regulate production of butyric acid in the gut system, increase overall production of short chain fatty acids, be utilized by the gut flora as prebiotics in the gut system and produce gas, reduce production of isobutyric acid and/or isovaleric acid, and/or lower pH to maintain intestinal microenvironment health.

8. Use according to claim 7, wherein the breast milk oligosaccharides in the infant formula are 3-SL and/or 6-SL for modulating butyrate production, preferably further reducing isobutyric acid and/or isovaleric acid production, in the distal colon.

9. Use according to claim 7, wherein the breast milk oligosaccharides in the infant formula are for use by the gut flora as prebiotics in the proximal colon and for gassing and/or lowering the pH of the proximal colon, the breast milk oligosaccharides being 3-SL and/or 6-SL.

10. Use according to claim 7, wherein the breast milk oligosaccharide in the infant formula is for increasing the overall production of beneficial short chain fatty acids comprising formic, acetic and/or propionic acid in the proximal and/or distal colon, the breast milk oligosaccharide being 3-SL and/or 6-SL.